Genome & Company Joins Global Pharmaceutical Firm Lilly’s Tune Labs to Accelerate AI Drug Development

조선일보

Lean Right

Factuality

Ownership

Genome & Company is embarking on new drug development by leveraging the artificial intelligence (AI) technology of global pharmaceutical company Eli Lilly. The plan is to reduce the time and cost involved in drug development through AI. According to the biotech industry on the 26th, Genome & Company is participating in Eli Lilly’s AI drug development platform, ‘Lilly Tune Labs.’ Lilly Tune Labs is a global innovative biotech initiative that work…